Lacking the ‘protective label’ of diabetes: Phenytoin-induced distal symmetrical peripheral neuropathy. A clinical case report

Mahon, Andrea M.

doi:10.1016/j.jtv.2016.06.006

Journal of Tissue Viability

2016

DOI: 10.1016/j.jtv.2016.06.006

|View full text |Cite

Lacking the ‘protective label’ of diabetes: Phenytoin-induced distal symmetrical peripheral neuropathy. A clinical case report

Andrea M. Mahon

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2017

Publication Types

Select...

Article2

Relationship

Self Cite0

Independent2

Authors

Journals

Cited by 2 publications

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Phenytoin: neuroprotection or neurotoxicity?

Hesselink¹,

Kopsky

2017

Neurol Sci

View full text Add to dashboard Cite

Phenytoin is an 80-year young molecule and new indications are still emerging. The neuroprotective potential of phenytoin has been evaluated for decades. Recently, a positive phase II trial supported its further development in the treatment of optic neuritis in multiple sclerosis. In 1942, however, peripheral neuritis was first reported to be an adverse event of phenytoin, and since then a small but steady stream of publications discussed peripheral polyneuropathy as being a possible adverse event of phenytoin. We have reviewed the literature and concluded there is some supportive evidence for a reversible polyneuropathy after the oral use of phenytoin, though with no evidence for clear neurotoxicity on the level of peripheral nerves. This is probably due to the fact that the pharmacological effects of phenytoin, based on the stabilizing effect of the voltage-gated sodium channels, make impairment of nerve conduction in asymptomatic and symptomatic reversible polyneuropathies plausible. Clear toxically-induced phenytoin-related polyneuropathies, however, are extremely rare and are always related to high dose or high plasma levels of phenytoin, mostly developing during many years of therapy. We could only find one case of a probable reversible chronic phenytoin intoxication resulting in a biopsy proven axonal atrophy with secondary demyelination and signs of remyelination. All case series and case reports published are insufficient in detail to prove a clear causal relation between phenytoin intake and the induction of a peripheral polyneuropathy. Phenytoin does not lead to irreversible toxicity of the peripheral nerves and might, on the other hand, have neuroprotective properties.

show abstract

Phenytoin: neuroprotection or neurotoxicity?

Hesselink¹,

Kopsky

2017

Neurol Sci

View full text Add to dashboard Cite

show abstract

Phenytoin

2017

Reactions Weekly

View full text Add to dashboard Cite

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Lacking the ‘protective label’ of diabetes: Phenytoin-induced distal symmetrical peripheral neuropathy. A clinical case report

Cited by 2 publications

References 10 publications

Phenytoin: neuroprotection or neurotoxicity?

Phenytoin: neuroprotection or neurotoxicity?

Phenytoin

Contact Info

Product

Resources

About